drugset / Trial / NCT00374907
A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this clinical research study is to learn whether Saxagliptin can improve the body's ability to make its own insulin and lower blood sugar in people with type 2 diabetes
Timeline
- Start
- 2006-09
- Primary completion
- 2008-01
- Completion
- 2009-12
Outcome
Met primary endpoint
registry Short Term Period: Saxagliptin 5 mg vs Short Term Period: Placebo; p = 0.0350; Adjusted Percent Difference 18.5 (95% CI 1.3 to 38.7) NCT00374907 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SAXAGLIPTIN ANHYDROUS | Small molecule | 5 mg | Oral |
| Comparator | Metformin | Small molecule | 500 mg | Oral |
| Comparator | Metformin | Small molecule | 1000 mg | Oral |
| Comparator | Metformin | Small molecule | 1500 mg | Oral |